CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
The company said its testing services revenues for the quarter rose nearly 120 percent year over year.
The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
Natera plans to harness One Lambda's commercial infrastructure when it launches its cfDNA kidney transplant rejection test this year.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The companies have agreed to distribute and codevelop diagnostics for the transplant monitoring market.
Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.